Stock Events

Stock Events

Kuros Biosciences 

CHF23.7
7
+CHF0.74+3.22% Today

Statistics

Day High
24.06
Day Low
23.44
52W High
23.98
52W Low
1.33
Volume
10,346.84
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10MarExpected
Q2 2023
Q3 2023
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
0
0.33
0.67
1
Expected EPS
0
Actual EPS
N/A

Financials

-5.68%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
151.11MRevenue
-8.58MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0RHR.LSE. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Orthofix Medical
OFIX
Mkt Cap470.09M
Orthofix Medical Inc. provides orthopedic and spine products, directly competing with Kuros in the field of bone healing and regeneration.
Stryker
SYK
Mkt Cap126.97B
Stryker Corporation offers a range of medical technologies, including orthobiologics, which competes with Kuros Biosciences' offerings.
Zimmer Biomet
ZBH
Mkt Cap18.01B
Zimmer Biomet Holdings, Inc. is a leader in musculoskeletal healthcare, competing in the orthobiologics space similar to Kuros.
Medtronic
MDT
Mkt Cap111.22B
Medtronic PLC provides medical technologies, systems, and services, including bone graft solutions that compete with Kuros Biosciences.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson, through its DePuy Synthes division, offers products that compete in the orthopedic and spine sector against Kuros.
Baxter International
BAX
Mkt Cap8.61B
Baxter International Inc. produces medical products including biosurgery materials that compete with Kuros Biosciences' surgical solutions.
Boston Scientific
BSX
Mkt Cap93.36B
Boston Scientific Corporation develops medical devices that are used in various surgical applications, competing with Kuros' biosurgery products.

About

Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the United Kingdom, and internationally. Its sealants pipeline products include Neuroseal EU and US for the treatment of dural sealant cranial. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase II clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase II clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase I trial for the treatment of spinal interbody fusion. The company has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. Kuros Biosciences AG is headquartered in Schlieren, Switzerland.
Show more...
CEO
Mr. Christopher T. Fair B.B.A.
Employees
178
Country
GB
ISIN
CH0325814116

Listings

SW
CH
KURN.SW
OTC Link
US
CSBTF
LSE
GB
0RHR.LSE
F
DE
YTSN.F

0 Comments

Share your thoughts

FAQ

What is Kuros Biosciences stock price today?▼
The current price of 0RHR.LSE is CHF23.7 CHF — it has increased by +3.22% in the past 24 hours. Watch Kuros Biosciences stock price performance more closely on the chart.
What is Kuros Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Kuros Biosciences stocks are traded under the ticker 0RHR.LSE.
Is Kuros Biosciences stock price growing?▼
0RHR.LSE stock has risen by +2.47% compared to the previous week, the month change is a -14.5% fall, over the last year Kuros Biosciences has showed a +31.45% increase.
When is the next Kuros Biosciences earnings date?▼
Kuros Biosciences is going to release the next earnings report on August 13, 2026.
What is Kuros Biosciences revenue for the last year?▼
Kuros Biosciences revenue for the last year amounts to 151.11M CHF.
What is Kuros Biosciences net income for the last year?▼
0RHR.LSE net income for the last year is -8.58M CHF.
How many employees does Kuros Biosciences have?▼
As of April 08, 2026, the company has 178 employees.
In which sector is Kuros Biosciences located?▼
Kuros Biosciences operates in the Energy sector.
When did Kuros Biosciences complete a stock split?▼
Kuros Biosciences has not had any recent stock splits.
Where is Kuros Biosciences headquartered?▼
Kuros Biosciences is headquartered in Schlieren, GB.